SCOTUS Protects ‘Skinny Label’ Marketing
The Supreme Court unanimously concluded a district court judge was right to dismiss Amarin’s infringement suit over claims its competitor encouraged doctors to prescribe its generic heart health drug for a treatment method covered by active Amarin patents, Michael Shapiro reports.
The suit was filed over claims Hikma was encouraging doctors to prescribe its generic version of Amarin’s Vascepa heart drug for a still-patented treatment method.
Drugmakers frequently obtain patents not just on chemical compounds they discover for novel drugs but separately for methods of using such drugs to treat various medical conditions. When ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.